With supplier issue now resolved, the Minnesota-run medtech company expects to “reach and then exceed” market growth in the ...

Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...

Boston Scientific announces favorable OPTION trial results for its WATCHMAN FLX LAAC device. In terms of stroke risk reduction, WATCHMAN FLX is found to be superior to OAC therapy.

CEO Geoff Martha said the business did not meet internal growth expectations last quarter due to third-party supply issues ...

Marlborough, Massachusetts Tuesday, November 19, 2024, 17:00 Hrs [IST] ...

At the moment, the company is developing novel therapeutic approaches for patients with underserved heart issues, such as ...

The trial compared the stroke prevention device for left atrial appendage closure to blood thinners in people who underwent ...

Boston Scientific, Medtronic and J&J are moving quickly to secure their place in the fast-growing pulsed field ablation space ...

Boston Scientific (BSX) stock climbed 5% after a study showed its Watchman FLX device was superior to oral anti-coagulants in reducing bleeding risks following cardiac ablation.

Left atrial appendage closure is an alternative strategy for stroke prophylaxis, Wazni and colleagues noted. "The safety and ...

Marie Thibault, an analyst from BTIG, maintained the Buy rating on Boston Scientific (BSX – Research Report). The associated price target ...